DVAX · As filed with the SEC
Dynavax Technologies income statement, by fiscal year
The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|
| Revenues: | |||
| Total revenues | 277,246 | 232,284 | 722,683 |
| Product revenue | 268,430 | 213,295 | 713,645 |
| Other revenue | 8,816 | 18,989 | 9,038 |
| Operating expenses: | |||
| Cost of sales - product | 49,445 | 50,167 | 262,153 |
| Research and development | 61,550 | 54,886 | 46,600 |
| Selling, general and administrative | 170,373 | 152,946 | 131,408 |
| Gain on sale of assets (Note 8) | 0 | (1,000) | (1,000) |
| Bad debt expense (Note 9) | 0 | 12,313 | 0 |
| Total operating expenses | 281,368 | 269,312 | 439,161 |
| (Loss) income from operations | (4,122) | (37,028) | 283,522 |
| Other (expense) income: | |||
| Interest income | 36,464 | 31,993 | 7,912 |
| Interest expense | (6,794) | (6,757) | (6,732) |
| Sublease income | 5,014 | 7,577 | 7,685 |
| Change in fair value of warrant liability (Note 14) | 0 | 0 | 1,801 |
| Other | 293 | (152) | 111 |
| Net income (loss) before income taxes | 30,855 | (4,367) | 294,299 |
| Provision for income taxes | (3,546) | (2,022) | (1,143) |
| Net income (loss) | 27,309 | (6,389) | 293,156 |
| Undistributed earnings allocated to participating securities | 0 | 0 | (283) |
| Net (loss) income allocable to common stockholders, basic (in USD per share) | 27,309 | (6,389) | 292,873 |
| Net income (loss) per share allocable to common stockholders | |||
| Basic (in USD per share) | 0.21 | (0.05) | 2.32 |
| Diluted (in USD per share) | 0.20 | (0.05) | 1.97 |
| Weighted-average shares used in computing net income (loss) per share allocable to common stockholders: | |||
| Basic (in shares) | 130,047 | 128,733 | 126,398 |
| Diluted (in shares) | 133,344 | 128,733 | 150,797 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.